Drug Profile
Vibostolimab - Merck Sharp & Dohme
Alternative Names: MK-7684Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase II Haematological malignancies; Malignant melanoma; Solid tumours
Most Recent Events
- 30 May 2023 Adverse events data and efficacy data from a phase I/II trial in Malignant melanoma presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 28 Oct 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Australia (IV, Infusion)
- 28 Oct 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Israel (IV, Infusion)